[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622392":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1",null,"Participants with obstructive hypertrophic cardiomyopathy receiving mavacamten treatment",[13],"Drug: Mavacamten",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Mavacamten","According to the product label",[9],[21],{"name":22,"affiliation":5,"role":23},"Bristol Myers Squibb","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"CMIC Co., Ltd","RECRUITING","Tokyo","Japan","JP",{"type":40,"coordinates":41},"Point",[42,43],139.69171,35.6895,{"lat":43,"lon":42},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100622392",false,"NCT07383025","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM) in Japan","Inclusion Criteria:\n\n• All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study\n\nExclusion Criteria:\n\n• Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study","ALL","18 Years",{"count":56,"type":57},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan",[61],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[63],"Obstructive hypertrophic cardiomyopathy (oHCM)","2026-01-26",{"date":66,"type":67},"2026-02-03","ACTUAL",{"date":69,"type":67},"2025-05-21",{"date":71,"type":57},"2029-11-30",{"name":5,"class":6},1]